{
    "@context": {
        "schema": "https://schema.org/",
        "dct": "http://purl.org/dc/terms/",
        "hg": "https://hormuz.group/data/ns#"
    },
    "id": "hg:company:ronak-darou-company",
    "identifier": "hg:company:ronak-darou-company",
    "dataset_type": "entity_dataset",
    "entity_type": "company",
    "data_version": "2.0",
    "generated_by": "Hormuz Data Layer 0.2.1",
    "generated_at": "2026-07-04T02:51:17+00:00",
    "name": "Ronak Darou Company",
    "slug": "ronak-darou-company",
    "status": "publish",
    "url": "https://hormuz.group/companies/ronak-darou-company/",
    "json_url": "https://hormuz.group/wp-content/uploads/hormuz-data/cpt/company/ronak-darou-company.json",
    "rest_url": "https://hormuz.group/wp-json/hormuz-data/v1/cpt/company/ronak-darou-company",
    "summary": "",
    "machine_summary": "Ronak Darou Company Ronak Darou Company is a private knowledge-based pharmaceutical manufacturer with a Tehran head office and manufacturing activity linked to Saveh. In the Hormuz Group company graph, it matters because it connects advanced generics, neurology, botulinum toxin, diabetes products, insulin, specialized injectables, domestic technology transfer, and patient-support programs. Its product portfolio makes it more technology-intensive than a basic generic-drug producer. Ronak Darou is relevant for investors assessing Iran's specialized pharmaceutical market, neurology and diabetes demand, advanced generics, botulinum-toxin localization, insulin access, and high-value medicine substitution under import constraints. It can support analysis of R&D capability, regulatory barriers, technology transfer, product differentiation, patient-support infrastructure, and export potential. Due diligence should verify ownership, manufacturing licenses, GMP status, product registrations, active production lines, API and biologic input sourcing, technology partners, export registrations, pharmacovigilance systems, intellectual-property exposure, and sanctions or payment-channel constraints. Ronak Darou Company develops, manufactures, markets, and supports specialized pharmaceutical products, including botulinum toxin type A, neurology medicines, epilepsy treatments, anticoagulants, diabetes medicines, insulin products, corticosteroids, pain and inflammation products, urology products, and selected injectable or advanced generic medicines. Its operations include R&D, patient-support activity, Tehran-based commercial operations, and a manufacturing base in Saveh. province: Tehran industry: Healthcare & Pharma, Manufacturing, Pharmaceuticals market: Consumer Demand, Healthcare, Materials, Supply Chains challenges: Compliance, Import Dependence, Supply Shortage, Technology Gap company_type: Manufacturer, Private Company city: Tehran",
    "published_at": "2026-06-28T20:29:05+00:00",
    "modified_at": "2026-06-28T20:29:05+00:00",
    "taxonomies": {
        "province": [
            {
                "id": 3,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/provinces/tehran/"
            }
        ],
        "industry": [
            {
                "id": 21,
                "name": "Healthcare & Pharma",
                "slug": "healthcare-pharma",
                "url": "https://hormuz.group/industry/healthcare-pharma/"
            },
            {
                "id": 16,
                "name": "Manufacturing",
                "slug": "manufacturing",
                "url": "https://hormuz.group/industry/manufacturing/"
            },
            {
                "id": 121,
                "name": "Pharmaceuticals",
                "slug": "pharmaceuticals",
                "url": "https://hormuz.group/industry/healthcare-pharma/pharmaceuticals/"
            }
        ],
        "market": [
            {
                "id": 34,
                "name": "Consumer Demand",
                "slug": "consumer-demand",
                "url": "https://hormuz.group/market/consumer-demand/"
            },
            {
                "id": 69,
                "name": "Healthcare",
                "slug": "healthcare",
                "url": "https://hormuz.group/market/consumer-demand/healthcare/"
            },
            {
                "id": 73,
                "name": "Materials",
                "slug": "materials",
                "url": "https://hormuz.group/market/enterprise-demand/materials/"
            },
            {
                "id": 76,
                "name": "Supply Chains",
                "slug": "supply-chains",
                "url": "https://hormuz.group/market/enterprise-demand/supply-chains/"
            }
        ],
        "challenges": [
            {
                "id": 164,
                "name": "Compliance",
                "slug": "compliance",
                "url": "https://hormuz.group/challenges/regulatory-barriers/compliance/"
            },
            {
                "id": 176,
                "name": "Import Dependence",
                "slug": "import-dependence",
                "url": "https://hormuz.group/challenges/market-gaps/import-dependence/"
            },
            {
                "id": 177,
                "name": "Supply Shortage",
                "slug": "supply-shortage",
                "url": "https://hormuz.group/challenges/market-gaps/supply-shortage/"
            },
            {
                "id": 179,
                "name": "Technology Gap",
                "slug": "technology-gap",
                "url": "https://hormuz.group/challenges/market-gaps/technology-gap/"
            }
        ],
        "company_type": [
            {
                "id": 299,
                "name": "Manufacturer",
                "slug": "manufacturer",
                "url": "https://hormuz.group/company-type/manufacturer/"
            },
            {
                "id": 307,
                "name": "Private Company",
                "slug": "private-company",
                "url": "https://hormuz.group/company-type/private-company/"
            }
        ],
        "city": [
            {
                "id": 384,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/cities/tehran/"
            }
        ]
    },
    "taxonomy_labels": {
        "province": "Tehran",
        "industry": "Healthcare & Pharma, Manufacturing, Pharmaceuticals",
        "market": "Consumer Demand, Healthcare, Materials, Supply Chains",
        "challenges": "Compliance, Import Dependence, Supply Shortage, Technology Gap",
        "company_type": "Manufacturer, Private Company",
        "city": "Tehran"
    },
    "fields_summary": {
        "legal_name": "Ronak Pharmaceutical Company",
        "website": "https://ronakpharm.com",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "",
        "listing_status": "private",
        "products_services": "Ronak Darou Company develops, manufactures, markets, and supports specialized pharmaceutical products, including botulinum toxin type A, neurology medicines, epilepsy treatments, anticoagulants, diabetes medicines, insulin products, corticosteroids, pain and inflammation products, urology products, and selected injectable or advanced generic medicines. Its operations include R&D, patient-support activity, Tehran-based commercial operations, and a manufacturing base in Saveh.",
        "export_relevance": "medium",
        "short_profile": "Ronak Darou Company is a private knowledge-based pharmaceutical manufacturer with a Tehran head office and manufacturing activity linked to Saveh. In the Hormuz Group company graph, it matters because it connects advanced generics, neurology, botulinum toxin, diabetes products, insulin, specialized injectables, domestic technology transfer, and patient-support programs. Its product portfolio makes it more technology-intensive than a basic generic-drug producer.",
        "investment_relevance": "Ronak Darou is relevant for investors assessing Iran's specialized pharmaceutical market, neurology and diabetes demand, advanced generics, botulinum-toxin localization, insulin access, and high-value medicine substitution under import constraints. It can support analysis of R&D capability, regulatory barriers, technology transfer, product differentiation, patient-support infrastructure, and export potential. Due diligence should verify ownership, manufacturing licenses, GMP status, product registrations, active production lines, API and biologic input sourcing, technology partners, export registrations, pharmacovigilance systems, intellectual-property exposure, and sanctions or payment-channel constraints."
    },
    "fields": {
        "rank_math_internal_links_processed": "1",
        "wp_statistics_words_count": "0",
        "legal_name": "Ronak Pharmaceutical Company",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "",
        "export_relevance": "medium",
        "verification_status": "basic",
        "data_confidence": "high",
        "listing_status": "private",
        "last_updated": "29/06/2026",
        "website": "https://ronakpharm.com",
        "products_services": "Ronak Darou Company develops, manufactures, markets, and supports specialized pharmaceutical products, including botulinum toxin type A, neurology medicines, epilepsy treatments, anticoagulants, diabetes medicines, insulin products, corticosteroids, pain and inflammation products, urology products, and selected injectable or advanced generic medicines. Its operations include R&D, patient-support activity, Tehran-based commercial operations, and a manufacturing base in Saveh.",
        "short_profile": "Ronak Darou Company is a private knowledge-based pharmaceutical manufacturer with a Tehran head office and manufacturing activity linked to Saveh. In the Hormuz Group company graph, it matters because it connects advanced generics, neurology, botulinum toxin, diabetes products, insulin, specialized injectables, domestic technology transfer, and patient-support programs. Its product portfolio makes it more technology-intensive than a basic generic-drug producer.",
        "investment_relevance": "Ronak Darou is relevant for investors assessing Iran's specialized pharmaceutical market, neurology and diabetes demand, advanced generics, botulinum-toxin localization, insulin access, and high-value medicine substitution under import constraints. It can support analysis of R&D capability, regulatory barriers, technology transfer, product differentiation, patient-support infrastructure, and export potential. Due diligence should verify ownership, manufacturing licenses, GMP status, product registrations, active production lines, API and biologic input sourcing, technology partners, export registrations, pharmacovigilance systems, intellectual-property exposure, and sanctions or payment-channel constraints.",
        "source_note": "Based on public company, official-company, pharmaceutical-sector, specialized medicine, R&D, product, and market-related information. Further verification is required before treating this profile as verified investment intelligence."
    },
    "field_profile": {
        "rank_math_internal_links_processed": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "wp_statistics_words_count": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "legal_name": {
            "type": "string",
            "present": true,
            "length": 28
        },
        "city": {
            "type": "string",
            "present": true,
            "length": 29
        },
        "ticker_symbol": {
            "type": "string",
            "present": false,
            "length": 0
        },
        "export_relevance": {
            "type": "string",
            "present": true,
            "length": 6
        },
        "verification_status": {
            "type": "string",
            "present": true,
            "length": 5
        },
        "data_confidence": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "listing_status": {
            "type": "string",
            "present": true,
            "length": 7
        },
        "last_updated": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "website": {
            "type": "string",
            "present": true,
            "length": 22
        },
        "products_services": {
            "type": "string",
            "present": true,
            "length": 483
        },
        "short_profile": {
            "type": "string",
            "present": true,
            "length": 465
        },
        "investment_relevance": {
            "type": "string",
            "present": true,
            "length": 720
        },
        "source_note": {
            "type": "string",
            "present": true,
            "length": 236
        }
    },
    "sources": [
        {
            "type": "note",
            "value": "Based on public company, official-company, pharmaceutical-sector, specialized medicine, R&D, product, and market-related information. Further verification is required before treating this profile as verified investment intelligence."
        }
    ],
    "quality": {
        "required_fields": [
            "legal_name",
            "website",
            "city",
            "listing_status",
            "products_services",
            "export_relevance",
            "verification_status",
            "data_confidence",
            "short_profile",
            "investment_relevance",
            "source_note",
            "last_updated"
        ],
        "missing_required_fields": [],
        "missing_required_count": 0,
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "29/06/2026",
        "stale_over_180_days": false,
        "quality_score": 100
    },
    "verification": {
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "29/06/2026"
    }
}